Vaccine Immunotherapy for Prostate Cancer
Abstract
The purpose of the research supported by this award is to conduct a Phase II clinical trial (study) of an adenovirus/PSA (Ad/PSA) vaccine for the treatment of prostate cancer. Two protocols have been used in the trial: #1 - Phase II study of Adenovirus/PSA vaccine in men with recurrent prostate cancer after local therapy; and #2 - Phase II study of Adenovirus/PSA vaccine in men with hormone refractory prostate cancer. In the first protocol men with newly recurrent prostate cancer were randomized to one of two arms of the study. Patients in Arm A received the Ad/PSA vaccine only; three injections spaced 30 days apart. Patients in Arm B received androgen deprivation therapy (ADT) followed at day 14 by the Ad/PSA vaccine, again with three injections. In the second protocol men with hormone refractory prostate cancer were injected with the vaccine only, three injections 30 days apart. The patients were followed for toxicity, the development of anti-PSA immune responses, and evidence of a clinical effect of the vaccination. The latter includes changes in serum PSA and prostatic acid phosphatase (PAP) levels and in the PSA doubling times (PSADT). Patients in protocol #2 also have CT and bone scans to monitor their prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2009
- Accession Number
- ADA509761
Entities
People
- David M. Lubaroff
Organizations
- University of Iowa